NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement

NovoCure Ltd

CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.
Company estimates approximately $13 million per month in lost revenue from CMS payors until privileges are reinstated.
NovoCure has filed a Corrective Action Plan and expects reinstatement, but cannot predict timing with certainty.
Company continues to provide services to existing and new patients; will attempt to bill for services during reinstatement.
Financial impact and ultimate outcome cannot be determined at this time.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.